Soligenix Reports Positive Phase 2 Results for Behçet's Disease Treatment
Soligenix announced positive top-line data from its phase 2 clinical trial evaluating SGX945 for treating aphthous ulcers in Behçet's disease, offering potential new options for this rare inflammatory condition with limited treatments.
Read the full story























